To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
TRPML1 Antibody
Antibody
Rabbit monoclonal antibody directed against mouse TRPML1. Developed for use in immunoblotting and immunocytochemistry applications. This antibody development project is part of the MJFF Targets to Therapies (T2T) Initiative. Anticipated Availability: Q4 2027
USP30 Antibody
Antibody
Rabbit monoclonal antibody directed against human/mouse USP30. Developed for use in immunocytochemistry, immunohistochemistry, and immunoprecipitation applications. This antibody development project is part of the MJFF Targets to Therapies (T2T) Initiative. Anticipated Availability: Q4 2027
Auxilin Antibody
Antibody
Rabbit monoclonal antibody directed against human/mouse auxilin for immunostaining applications. Estimated Availability: Mid 2026
GALC Antibody
Antibody
Rabbit monoclonal antibody directed against human/mouse GALC for immunoblotting applications. Estimated Availability: Late 2025
Miro1 Antibody
Antibody
Rabbit monoclonal antibody directed against human/mouse Miro1 for immunocytochemistry applications. Estimated Availability: Late 2025
PINK1 pS228 Phosphospecific Antibody
Antibody
Rabbit monoclonal phosphospecific antibody directed against Serine 228 of PINK1 (pS228 PINK1). Developed for use in immunoblotting applications.Expected Availability: Late 2025
TMEM175 Antibody
Antibody
Rabbit monoclonal antibody directed against human/mouse TMEM175. Developed for us in immunoblotting and immunostaining applications. Estimated Availability: Late 2025
Eif2ak1 Knockout RAW264.7 Cell Line
Immortalized Cell
RAW264.7 cell line with homozygous knockout of Eif2ak1. Anticipated Availability: Q4 2026
CLN3 Knockout HCT-116 Cell Line
Immortalized Cell
HCT-116 cell line with homozygous knockout of CLN3. This cell line development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative. Anticipated Availability: Q4 2026
ITPKB Knockout PC-3 Cell Line
Immortalized Cell
PC-3 cell line with homozygous knockout of ITPKB. This cell line development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative. Anticipated Availability: Q4 2026
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic